{"disease":{"id":"carcinoma-squamous-cell-of-head-and-neck","name":"carcinoma squamous cell of head and neck"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05621837","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05845632","title":"Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":965,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT00957086","title":"Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":710,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT07361666","title":"Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","has_results":false},{"nct_id":"NCT03485209","title":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Simcha IL-18, Inc.","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT05721755","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":290,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT02383966","title":"Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":243,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT01836029","title":"Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT01307267","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05329532","title":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03509012","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02101034","title":"PD 0332991 and Cetuximab in Patients With Incurable SCCHN","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT02573493","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03370276","title":"Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03148665","title":"Saliva-based Detection of CD44","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Joseph Califano","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT05482880","title":"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT03540563","title":"ctDNA as a Biomarker for Treatment Response in HNSCC","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT05983133","title":"A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02296684","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03574792","title":"Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05747625","title":"(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Eben Rosenthal","has_results":false},{"nct_id":"NCT03620123","title":"A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT00446446","title":"PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00494182","title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02289209","title":"Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Dan Zandberg","has_results":true},{"nct_id":"NCT02952989","title":"A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT07419464","title":"5-Fluorouracil Response and Optimization STudy (The FROST Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Washington University School of Medicine","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}